IOL Chem & Pharma
Ticker >

IOL Chem & Pharma share price

IOL Chemicals And Pharmaceuticals Ltd.

NSE: IOLCP BSE: 524164 SECTOR: Pharmaceuticals & Drugs  189k   2k   310

390.65
-0.65 (-0.17%)
BSE: 18 Apr 04:01 PM

Price Summary

Today's High

₹ 398

Today's Low

₹ 387.65

52 Week High

₹ 535.6

52 Week Low

₹ 350.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2293.33 Cr.

Enterprise Value

₹ 2352.06 Cr.

No. of Shares

5.87 Cr.

P/E

13.29

P/B

1.42

Face Value

₹ 10

Div. Yield

1.02 %

Book Value (TTM)

₹  274.6

CASH

₹ 20.9 Cr.

DEBT

₹ 79.63 Cr.

Promoter Holding

48.19 %

EPS (TTM)

₹  29.38

Sales Growth

1.52%

ROE

9.66 %

ROCE

13.64%

Profit Growth

-15.5 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year1.52%
3 Year5.38%
5 Year17.66%

Profit Growth

1 Year-15.5%
3 Year-27.1%
5 Year38.27%

ROE%

1 Year9.66%
3 Year21.74%
5 Year38.34%

ROCE %

1 Year13.64%
3 Year28.34%
5 Year41.72%

Debt/Equity

0.0529

Price to Cash Flow

18.62

Interest Cover Ratio

12.5051608986035

CFO/PAT (5 Yr. Avg.)

0.992389796690378

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 48.19 0
Dec 2023 48.19 0
Sep 2023 48.19 0
Jun 2023 48.19 0
Mar 2023 48.19 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 21.7425626587226% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.3352678328201% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.5051608986035.
  • The Company has been maintaining an effective average operating margins of 21.3278367773702% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 55.4501956436158 days.

 Limitations

  • The company has shown a poor profit growth of -27.0984633431403% for the Past 3 years.
  • The company has shown a poor revenue growth of 5.38196082146054% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 523.48 587.21 563.18 545.3 520.39
Total Expenditure 480.44 491.42 490.32 481.2 475.91
Operating Profit 43.04 95.79 72.86 64.1 44.48
Other Income 6.64 8.72 7.06 7.11 8.38
Interest 4.7 4.88 3.95 4.44 4.3
Depreciation 11.73 12.1 14.44 15.67 16.32
Exceptional Items 0 0 0 0 0
Profit Before Tax 33.25 87.53 61.53 51.1 32.24
Tax 9.1 22.26 15.32 13.31 9.01
Profit After Tax 24.15 65.27 46.21 37.79 23.23
Adjusted EPS (Rs) 4.11 11.12 7.87 6.44 3.96

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1685.33 1894.47 1966.98 2184.02 2217.11
Total Expenditure 1275.68 1320.59 1375.14 1927.74 1990.59
Operating Profit 409.65 573.88 591.84 256.28 226.52
Other Income 10.37 16.02 24.3 32.04 25.57
Interest 51.42 20.93 5.83 8.29 16.47
Depreciation 32.45 35.73 38.92 43.26 46.13
Exceptional Items 0 0 0 -13.93 0
Profit Before Tax 336.15 533.24 571.39 222.84 189.49
Tax 99.45 171.95 126.83 57.18 49.51
Net Profit 236.7 361.29 444.56 165.66 139.98
Adjusted EPS (Rs.) 41.61 63.51 75.72 28.22 23.84

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 56.89 56.89 58.71 58.71 58.71
Total Reserves 417.45 756.65 1201.72 1331.56 1447.84
Borrowings 189.88 0 0 0 0
Other N/C liabilities 20.77 79.73 59.11 56.62 58.15
Current liabilities 324.79 453.63 432.8 575.29 502.17
Total Liabilities 1009.78 1346.9 1752.34 2022.18 2066.87
Assets
Net Block 411.72 469.04 512.36 560.64 751.31
Capital WIP 27.02 19.19 48.27 102.03 81.4
Intangible WIP 0 0 0 3.17 8.24
Investments 0 0 0 0.1 17.71
Loans & Advances 11.56 1.33 17.61 10.77 9.52
Other N/C Assets 7.3 9.43 21.95 204.87 233.36
Current Assets 552.18 847.91 1152.15 1140.6 965.33
Total Assets 1009.78 1346.9 1752.34 2022.18 2066.87
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 336.15 533.24 571.39 222.84 189.49
Adjustment 82.35 51.93 27.15 33.12 44.42
Changes in Assets & Liabilities -77.64 2.78 -76.51 -102.34 -63.67
Tax Paid -67.69 -117.15 -142.25 -62.58 -47.1
Operating Cash Flow 273.17 470.8 379.78 91.04 123.14
Investing Cash Flow -63.04 -184.23 -317.25 -120.62 -119.19
Financing Cash Flow -197.46 -271.89 -58.28 -1.64 -4.11
Net Cash Flow 12.67 14.68 4.25 -31.22 -0.16

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 48.19 48.19 48.19 48.19 48.19
maya devi polycot limited... 21.54 21.54 21.54 21.54 21.54
ncvi enterprises limited 4.79 4.79 15.96 15.96 15.96
nm merchantiles pvt limit... - - - - 8.65
varinder gupta 2.04 2.04 2.04 2.04 2.04
nm merchantiles private l... - - - 8.65 -
nm merchantiles limited 8.65 8.65 8.65 - -
bhudeva lifesciences limi... 4.90 4.90 - - -
ncg enterprises limited 5.59 5.59 - - -
true value traders limite... 0.68 0.68 - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 51.81 51.81 51.81 51.81 51.81
enorg limited 4.43 4.43 4.43 4.43 4.43
g consultants and fabrica... - - - - 1.68
vasudeva commercials limi... 7.94 7.94 7.94 7.94 7.94
g consultants and fabrica... 1.68 1.68 1.68 1.68 -
pinebridge global funds -... 1.05 1.05 1.05 1.05 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

IOL Chemicals completes ANVISA GMP audit of 10 manufacturing units without any observation19 Mar 2024, 12:30PM IOL Chemicals gets approval for ‘Metformin Hydrochloride’ from CDE in China19 Feb 2024, 3:37PM IOL Chemicals gets nod to wind up ‘M/s IOL Global’ in UK7 Feb 2024, 3:30PM IOL Chemicals and Pharmaceuticals reports marginal fall in Q3 consolidated net profit7 Feb 2024, 2:24PM IOL Chem & Pharma - Quaterly Results6 Feb 2024, 6:15PM IOL Chem & Pharma - Quaterly Results6 Feb 2024, 6:15PM IOL Chem & Pharma - Quaterly Results6 Feb 2024, 6:15PM Iol Chemicals & Pharmaceuticals informs about analyst meet13 Dec 2023, 2:36PM IOL Chem & Pharma - Quaterly Results8 Nov 2023, 4:06PM IOL Chem & Pharma - Quaterly Results8 Nov 2023, 4:06PM IOL Chem & Pharma - Quaterly Results8 Nov 2023, 4:06PM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep 2023, 10:16AM IOL Chemicals and Pharmaceuticals informs about disclosure 28 Sep 2023, 10:16AM IOL Chem & Pharma - Quaterly Results9 Aug 2023, 6:05PM IOL Chem & Pharma - Quaterly Results9 Aug 2023, 6:05PM IOL Chemicals & Pharmaceuticals informs about details of loss of certificate25 Jul 2023, 4:04PM Iol Chemicals & Pharmaceuticals informs about press release4 Jul 2023, 12:17PM IOL Chemicals commences Plant for Acetic Anhydride12 Jun 2023, 4:00PM IOL Chemicals & Pharmaceuticals informs about presentation 3 Jun 2023, 12:08PM IOL Chemicals and Pharmaceuticals informs about investor conference call8 May 2023, 4:51PM IOL Chemicals and Pharmaceuticals informs about press release8 May 2023, 2:11PM IOL Chemicals gets Certificate of Suitability to export Paracetamol in European market8 May 2023, 12:29PM Iol Chemicals & Pharmaceuticals informs about press release29 Apr 2023, 3:38PM Iol Chemicals & Pharmaceuticals informs about loss of share certificate29 Apr 2023, 3:16PM IOL Chemicals and Pharmaceuticals reports 2- fold jump in Q4 consolidated net profit28 Apr 2023, 4:15PM IOL Chemicals & Pharmaceuticals informs about outcome of board meeting28 Apr 2023, 3:20PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chemicals & Pharmaceuticals informs about clarification on price movement21 Apr 2023, 12:49PM IOL Chemicals & Pharmaceuticals informs about press release5 Apr 2023, 10:52AM Iol Chemicals & Pharmaceuticals informs about analyst meet10 Mar 2023, 12:37PM IOL Chemicals and Pharmaceuticals reports 40% fall in Q3 net profit8 Feb 2023, 2:07PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chemicals and Pharmaceuticals informs about board meeting 1 Feb 2023, 5:19PM IOL Chemicals and Pharmaceuticals incorporates wholly owned subsidiary in UK1 Feb 2023, 3:17PM IOL Chemicals and Pharmaceuticals informs about analyst meet 6 Dec 2022, 4:45PM IOL Chemicals and Pharmaceuticals receives patent from Government of India24 Nov 2022, 12:21PM IOL Chemicals and Pharmaceuticals informs about transcript of earnings call19 Nov 2022, 3:55PM IOL Chemicals and Pharmaceuticals gets nod to incorporate wholly owned subsidiary16 Nov 2022, 11:40AM IOL Chemicals and Pharmaceuticals reports 69% fall in Q2 consolidated net profit15 Nov 2022, 4:10PM IOL Chem & Pharma - Quaterly Results14 Nov 2022, 6:27PM IOL Chem & Pharma - Quaterly Results14 Nov 2022, 6:27PM IOL Chemicals gets CEP to supply Pantoprazole Sodium Sesquihydrate API in Europe8 Nov 2022, 11:01AM IOL Chemicals and Pharmaceuticals informs about disclosure 3 Nov 2022, 10:51AM IOL Chemicals and Pharmaceuticals informs about loss of share certificate13 Oct 2022, 5:05PM IOL Chemicals receives REACH certification for supply of ethyl acetate across European markets8 Oct 2022, 4:15PM IOL Chemicals and Pharmaceuticals gets nod to invest $2.1 million in USpharma23 Sep 2022, 11:38AM

IOL Chem & Pharma Stock Price Analysis and Quick Research Report. Is IOL Chem & Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into IOL Chem & Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. IOL Chem & Pharma cash from the operating activity was Rs 123.14 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. IOL Chem & Pharma has a Debt to Equity ratio of 0.0529 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In IOL Chem & Pharma , the EPS growth was -15.5018127562755 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, IOL Chem & Pharma has OPM of 10.2169039876235 % which is a bad sign for profitability.
     
  • ROE: IOL Chem & Pharma have a poor ROE of 9.66439060763182 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of IOL Chem & Pharma is Rs 389.05. One can use valuation calculators of ticker to know if IOL Chem & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about IOL Chem & Pharma

IOL Chemicals And Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

IOL Chemicals And Pharmaceuticals Ltd. is a renowned pharmaceutical company that specializes in manufacturing bulk drugs, specialty chemicals, and intermediates. With a strong focus on research and development, IOL Chemicals has established a reputation for producing high-quality products that meet international standards. The company's commitment to innovation and customer satisfaction has positioned it as a trusted partner for various healthcare and pharmaceutical organizations around the globe.

IOL Chemicals And Pharmaceuticals Ltd. - Share Price

The share price of IOL Chemicals And Pharmaceuticals Ltd. is an important aspect of the company's stock analysis. It reflects the market's perception of the company's performance, growth potential, and overall value. Investors can find the latest share price of IOL Chemicals on our website, along with historical data and interactive price charts to help analyze trends and patterns over time.

IOL Chemicals And Pharmaceuticals Ltd. - Balance Sheet

Analyzing the balance sheet of IOL Chemicals And Pharmaceuticals Ltd. provides essential insights into the company's financial health and stability. Our pre-built screening tools allow long-term stock investors to assess the company's assets, liabilities, and equity in a structured manner. For a more in-depth analysis, our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Annual Report

The annual report of IOL Chemicals And Pharmaceuticals Ltd. serves as a comprehensive overview of the company's performance, achievements, and future prospects. Our website provides downloadable copies of the company's annual reports, enabling investors to delve deeper into the financial statements, management's discussions and analysis, and other significant information essential for stock analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Dividend

For investors seeking regular income from their investments, dividends play a crucial role in stock analysis. IOL Chemicals And Pharmaceuticals Ltd. has a track record of rewarding its shareholders with consistent dividend payouts. Our website provides information on the company's dividend history, payout ratio, and dividend yield, aiding investors in assessing the potential returns they may receive through dividend income.

IOL Chemicals And Pharmaceuticals Ltd. - Quarterly Result

Staying updated with the latest quarterly results is vital in stock analysis, as it allows investors to evaluate a company's financial performance and identify any emerging trends or concerns. Our website offers access to IOL Chemicals And Pharmaceuticals Ltd.'s quarterly results, including key financial indicators, revenue growth, profit margins, and other relevant metrics. This information can be combined with our premium features to facilitate fair value calculations.

IOL Chemicals And Pharmaceuticals Ltd. - Stock Price

Monitoring the stock price of IOL Chemicals And Pharmaceuticals Ltd. is crucial for investors to make informed decisions. Our website provides real-time and historical stock prices along with interactive price charts to help analyze market trends. Investors can also utilize our pre-built screening tools to filter stocks based on specific criteria and compare the performance of IOL Chemicals with its peers.

IOL Chemicals And Pharmaceuticals Ltd. - Price Chart

The price chart of IOL Chemicals And Pharmaceuticals Ltd. visualizes the historical movement of the stock price over time. By examining the price chart, investors can identify patterns, trends, and support-resistance levels, aiding in technical analysis. Our website provides interactive price charts with various customization options, allowing investors to analyze and interpret the stock price movements in the desired time frame.

IOL Chemicals And Pharmaceuticals Ltd. - News

Staying updated with the latest news and developments related to IOL Chemicals And Pharmaceuticals Ltd. is crucial for stock analysis. Our website offers a dedicated section for company news, where investors can find the latest announcements, press releases, regulatory updates, and other relevant information. This comprehensive news coverage ensures that investors stay well-informed and make data-driven decisions.

IOL Chemicals And Pharmaceuticals Ltd. - Concall Transcripts

Concall transcripts provide valuable insights into the discussions and strategies shared during the company's conference calls with analysts and investors. Our website provides downloadable concall transcripts of IOL Chemicals And Pharmaceuticals Ltd., enabling investors to gain a deeper understanding of the company's outlook, growth plans, and response to market dynamics. These transcripts are essential for long-term stock investors seeking a comprehensive stock analysis.

IOL Chemicals And Pharmaceuticals Ltd. - Investor Presentations

Investor presentations serve as a valuable resource for understanding a company's performance, growth strategies, and future prospects. Our website offers downloadable investor presentations of IOL Chemicals And Pharmaceuticals Ltd., providing investors with detailed insights into the company's business model, financial performance, and market positioning. These presentations are a valuable tool for stock analysis, helping investors make informed investment decisions.

IOL Chemicals And Pharmaceuticals Ltd. - Promoters

Promoters play a significant role in influencing a company's direction, decisions, and growth. IOL Chemicals And Pharmaceuticals Ltd. boasts a dedicated and experienced group of promoters who have been instrumental in shaping the company's success. Our website provides comprehensive information about the promoters of IOL Chemicals, including their background, expertise, and significant contributions to the company's growth story.

IOL Chemicals And Pharmaceuticals Ltd. - Shareholders

Understanding the ownership structure and major shareholders of a company is vital for stock analysis. Our website provides information on the major shareholders of IOL Chemicals And Pharmaceuticals Ltd., helping investors gauge the level of institutional interest and the distribution of ownership. Such insights enable investors to assess the confidence that other market participants have in the company and make informed investment decisions.

Please note that our website offers additional premium features, including fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Additionally, we provide various pre-built screening tools that help investors filter stocks based on specific criteria for a more focused stock analysis.

(Note: This content is tailored specifically for a website and does not contain any financial data points, numbers, or a conclusion.)

Read More
X